secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0001104659-21-140321
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3
--------------------------------------------------------------------------------

- Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.
- ELX-02 well tolerated; no treatment-related serious adverse events; most common mild injection site reactions.
- Planning for Phase 3 clinical development initiated; 1.5 mg/kg/day dose selected for further study.
- First patient dosed in Phase 2 combination arm with ivacaftor; topline data expected by H1 2022.
- Evaluation of inhaled delivery of ELX-02 started; IND submission planned for H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/0001104659-21-140321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/tm2133239d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-140321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer